RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.27
+1.64%Aug 6, 2026, 00:00 UTC
Cartesian Therapeutics reported Q2 2026 results with net income of $15.8 million and diluted EPS of $0.46, and cash and cash equivalents of $149.3 million at quarter end.
Aug 6, 2026, 00:00 UTC
Cartesian Therapeutics entered into a credit facility with total potential non-dilutive funding of up to $150 million, with a first funded tranche of $50 million.
Jun 9, 2026, 17:31 UTC
Cartesian Therapeutics entered into a strategic licensing agreement with WestGene Biopharma.
Source: